SAB Biotherapeutics (NASDAQ:SABS) Price Target Raised to $12.00 at Leerink Partners

SAB Biotherapeutics (NASDAQ:SABS) had its price objective hoisted by Leerink Partners from $7.00 to $12.00 in a report issued on Monday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ target price suggests a potential upside of 260.36% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Citigroup initiated coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target for the company. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SAB Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $11.63.

SAB Biotherapeutics Price Performance

SABS opened at $3.33 on Monday. The firm has a market cap of $254.63 million, a P/E ratio of -1.58 and a beta of 0.54. The firm has a 50-day moving average of $3.70 and a 200 day moving average of $3.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, research analysts expect that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth about $8,847,000. Simplify Asset Management Inc. purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $779,000. Propel Bio Management LLC purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $2,442,000. Jefferies Financial Group Inc. purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $2,170,000. Finally, Perceptive Advisors LLC lifted its holdings in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after buying an additional 5,628,533 shares in the last quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.